Ultragenyx Pharmaceutical Statistics
Total Valuation
RARE has a market cap or net worth of $2.76 billion. The enterprise value is $3.16 billion.
Important Dates
The next estimated earnings date is Tuesday, November 4, 2025, after market close.
Earnings Date | Nov 4, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
RARE has 96.20 million shares outstanding. The number of shares has increased by 19.24% in one year.
Current Share Class | 96.20M |
Shares Outstanding | 96.20M |
Shares Change (YoY) | +19.24% |
Shares Change (QoQ) | +2.26% |
Owned by Insiders (%) | 3.49% |
Owned by Institutions (%) | 99.04% |
Float | 92.80M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 4.66 |
Forward PS | 3.86 |
PB Ratio | 18.74 |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 5.18 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.45, with a Debt / Equity ratio of 5.58.
Current Ratio | 2.45 |
Quick Ratio | 2.10 |
Debt / Equity | 5.58 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -8.47 |
Financial Efficiency
Return on equity (ROE) is -180.44% and return on invested capital (ROIC) is -26.31%.
Return on Equity (ROE) | -180.44% |
Return on Assets (ROA) | -21.59% |
Return on Invested Capital (ROIC) | -26.31% |
Return on Capital Employed (ROCE) | -49.86% |
Revenue Per Employee | $471,529 |
Profits Per Employee | -$411,849 |
Employee Count | 1,294 |
Asset Turnover | 0.42 |
Inventory Turnover | 17.96 |
Taxes
In the past 12 months, RARE has paid $2.54 million in taxes.
Income Tax | 2.54M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -51.63% in the last 52 weeks. The beta is 0.21, so RARE's price volatility has been lower than the market average.
Beta (5Y) | 0.21 |
52-Week Price Change | -51.63% |
50-Day Moving Average | 29.27 |
200-Day Moving Average | 37.22 |
Relative Strength Index (RSI) | 39.94 |
Average Volume (20 Days) | 1,422,610 |
Short Selling Information
The latest short interest is 8.32 million, so 8.65% of the outstanding shares have been sold short.
Short Interest | 8.32M |
Short Previous Month | 8.41M |
Short % of Shares Out | 8.65% |
Short % of Float | 8.97% |
Short Ratio (days to cover) | 5.22 |
Income Statement
In the last 12 months, RARE had revenue of $610.16 million and -$532.93 million in losses. Loss per share was -$5.52.
Revenue | 610.16M |
Gross Profit | -167.80M |
Operating Income | -505.09M |
Pretax Income | -586.86M |
Net Income | -532.93M |
EBITDA | -469.65M |
EBIT | -505.09M |
Loss Per Share | -$5.52 |
Full Income Statement Balance Sheet
The company has $487.59 million in cash and $882.91 million in debt, giving a net cash position of -$343.87 million or -$3.57 per share.
Cash & Cash Equivalents | 487.59M |
Total Debt | 882.91M |
Net Cash | -343.87M |
Net Cash Per Share | -$3.57 |
Equity (Book Value) | 158.29M |
Book Value Per Share | 1.57 |
Working Capital | 426.54M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$421.25 million and capital expenditures -$6.06 million, giving a free cash flow of -$427.30 million.
Operating Cash Flow | -421.25M |
Capital Expenditures | -6.06M |
Free Cash Flow | -427.30M |
FCF Per Share | -$4.44 |
Full Cash Flow Statement Margins
Gross margin is -27.50%, with operating and profit margins of -82.78% and -87.34%.
Gross Margin | -27.50% |
Operating Margin | -82.78% |
Pretax Margin | -86.93% |
Profit Margin | -87.34% |
EBITDA Margin | -76.97% |
EBIT Margin | -82.78% |
FCF Margin | n/a |
Dividends & Yields
RARE does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -19.24% |
Shareholder Yield | -19.24% |
Earnings Yield | -18.90% |
FCF Yield | -15.15% |
Dividend Details Analyst Forecast
The average price target for RARE is $86.64, which is 201.78% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $86.64 |
Price Target Difference | 201.78% |
Analyst Consensus | Strong Buy |
Analyst Count | 14 |
Revenue Growth Forecast (5Y) | 33.01% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
RARE has an Altman Z-Score of -2.78 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -2.78 |
Piotroski F-Score | 4 |